Summit Therapeutics (NASDAQ: SMMT) will present at the Barclays 26th Global Healthcare Conference in Miami Beach, FL from March 12-14, 2024. CEO Dr. Maky Zanganeh and Chairman Robert W. Duggan will discuss the innovative investigational bispecific antibody, ivonescimab, on March…
ResearchAndMarkets.com is pleased to announce the addition of the “FARXIGA Market Size, Forecast, and Emerging Insight – 2032” report to its offerings. This comprehensive report delves into the impact and projected growth of FARXIGA in the treatment landscape of myocardial…
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has revealed that Jannie Oosthuizen, President of Human Health U.S., is set to engage in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on…
Transgene (Euronext Paris: TNG), a biotechnology company specializing in virus-based immunotherapies for cancer treatment, NEC Corporation (NEC; TSE: 6701), a leader in IT, network, and AI technologies, and BostonGene Corporation (BostonGene), a prominent AI-based molecular and immune profiling firm, have…
United Therapeutics Corporation (Nasdaq: UTHR), a leading public benefit corporation, has disclosed that Patrick Poisson, Executive Vice President of Technical Operations, will participate in a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.…
Epsilogen and Lonza Achieve Breakthrough in Manufacturing IgE Antibody for Ovarian Cancer Treatment Epsilogen, a leader in developing IgE antibodies for cancer therapy, and Lonza, a global partner in pharmaceutical manufacturing, have announced the successful completion of Good Manufacturing Practice…
Shionogi & Co., Ltd. (Headquartered in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; referred to as “Shionogi” hereafter) has initiated the second phase of collaboration with Nagasaki University (Located in Nagasaki, Nagasaki Prefecture; President: Takeshi Nagayasu), focusing on comprehensive cooperation in…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) has initiated dosing for the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an investigational oral, nonhormonal compound aimed at addressing vasomotor symptoms (VMS) linked…
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion regarding the expansion of the label for KALYDECO® (ivacaftor) to include the treatment…
Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Reblozyl® (luspatercept) for the treatment of adult patients with transfusion-dependent anemia due to…
Carlos Mercado experienced a sudden onset of symptoms reminiscent of a heart attack while settling down for an evening of television in 2022. The racing heart, chest pain, and cold sweats mirrored a previous episode he had endured over a…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of oral, small molecule protease inhibitors, has announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Innovation Passport…
